OTC Watch

All stocks / CLCS

Cell Source, Inc. CLCS

Cell Source (CLCS): shares outstanding up 51% in a year and the latest annual figures in plain language. Each fact links to its SEC filing.

DilutionEstimated float Pink LimitedNew York, USA
Live quote on OTC Markets

Market listing

Full name
CELL SOURCE INC
Market tier
OTC Pink Limited
Trading status
Active
Last trade
Nov 16
Website
www.cell-source.com
Source: Stockwatch, 2026-11-17

News headlines

Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week
2026-05-21 09:00 · News Release
Cell Source, Inc. to Present at the LD Micro Invitational XVI
2026-05-14 16:01 · News Release
Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent
2026-01-15 16:01 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2024-12-31
The report says
Net loss
($4,512,642)
What it means

It spends more than it earns

Under strain

The company lost $4.5 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$74,631
Net cash used in operating activities
($2,684,162)
What it means

The cash could run out soon

Under strain

It had $74,631 in the bank and used about $223,680 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.

The report says
Total assets
$286,500
Total liabilities
$18,824,336
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $286,500. Its debts and unpaid bills add up to $18.8 million. That is about $65.70 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Dilution2026-05-13

Shares outstanding rose from 45,038,244 (2025-03-31) to 67,945,856 (2026-05-13), up 51%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-05-13

Estimated float about 67,945,856 shares as of 2026-05-13: 67,945,856 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2024-07-23
41.9M
2024-08-14
41.9M
2024-09-30
43.3M
2024-11-13
43.5M
2024-12-31
45.0M
2025-03-31
45.0M
2026-04-06
67.9M
2026-05-13
67.9M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-05-14 10-Q10-Q
2026-04-07 10-K10-K

Common questions about CLCS

Does CLCS file reports with the SEC?

Yes. Cell Source files with the SEC under company number 0001569340. The most recent filing we hold is a 10-Q dated 2026-05-14.

Source record

How many CLCS shares are outstanding?

67,945,856 shares as of 2026-05-13, as reported to the SEC. That is up 51% from 45,038,244 on 2025-03-31.

Source record

Has CLCS filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Is Cell Source making money?

The company lost $4.5 million in the year. It reported no sales. (Annual figures to 2024-12-31. Facts from the company's own report, not a recommendation.)

Source record